Clinical Trials Directory

Trials / Completed

CompletedNCT01131507

PR-018: An Open-Label, Safety Extension of Study PR-011

A Multicenter, Open-Label, Safety Extension of Study PR-011 Titled: A Multicenter, Randomized, Open-Label, Crossover Study to Evaluate the Mode of Administration and Safety of EUR-1008 in Infants 1 to 12 Months of Age With Exocrine Pancreatic Insufficiency (EPI) Associated With Cystic Fibrosis (CF)

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
15 (actual)
Sponsor
Forest Laboratories · Industry
Sex
All
Age
12 Months
Healthy volunteers
Not accepted

Summary

A study to evaluate long term safety and effect on ability to thrive of EUR-1008 (APT-1008) 3,000 lipase units (Zenpep® \[pancrelipase\] delayed release capsules) in infants with exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF).

Detailed description

This is a multi-center, open-label, safety extension of Aptalis (formerly Eurand) study PR-011 (NCT01100606) in pediatric participants with EPI due to CF. The study will be carried out in participants who completed the PR-011 study. The study is comprised of 5 visits: an enrollment visit, treatment visit 1 (3 months), treatment visit 2 (6 months), treatment visit 3 (9 months) and treatment visit 4 (12 months). Once determined eligible for participation, participants will be enrolled into the study.

Conditions

Interventions

TypeNameDescription
DRUGEUR-1008 (APT-1008)EUR-1008 (APT-1008) (Zenpep® \[pancrelipase\] 3,000 lipase units delayed release capsules) from open capsules mixed with a small amount of apple juice or apple sauce will be administered orally starting at the same dose as administered at the end of study PR-011 (NCT01100606), with dose increments of 3,000 lipase units. The dose will be adjusted based on participants' age and body weight. Total dose will not exceed 10,000 lipase units per kilogram (kg) of body weight per day unless clinically indicated. Total duration of study treatment will be up to 12 months.

Timeline

Start date
2010-07-01
Primary completion
2011-12-01
Completion
2011-12-01
First posted
2010-05-27
Last updated
2017-03-21
Results posted
2014-03-07

Locations

6 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01131507. Inclusion in this directory is not an endorsement.